35 results on '"Leon, Kalet"'
Search Results
2. Characterizing steady states of genome-scale metabolic networks in continuous cell cultures
3. Stochastic approximation to the specific response of the immune system
4. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC
5. Mathematical Models of the Role of IL-2 in the Interactions Between Helper and Regulatory CD4+ T Cells
6. Unraveling a Conserved Conformation of the FG Loop upon the Binding of Natural Ligands to the Human and Murine PD1
7. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: A versatile platform for fine epitope mapping
8. Treatment of Systemic Inflammation with Itolizumab: A Single Center Experience
9. Deciphering PD1 activation mechanism from molecular docking and molecular dynamic simulations
10. HEK293 producing the extracellular domain HER1: Full datasets of continuous fermentation process and metabolites analysis
11. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines
12. Differential Effects of IL2Rα and IL15Rα over the Stability of the Common Beta-Gamma Signaling Subunits of the IL2 and IL15 Receptors
13. An Anti-CD6 Antibody for the Treatment of COVID-19 Patients with Cytokine-Release Syndrome: Report of Three Cases
14. Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
15. In-silico media optimization for continuous cultures using genome scale metabolic networks: the case of CHO-K1
16. Modulation of CD4 T cell function via CD6-targeting
17. Immunological self-tolerance: Lessons from mathematical modeling
18. When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells
19. Abstract CT088: Final results of the Phase I study of nivolumab in combination with CIMAvax, an epidermal growth factor(EGF)-depleting immunotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Focus on biomarker analyses
20. Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19.
21. Characterizing steady states of genome-scale metabolic networks in continuous cell cultures
22. Abstract B120: Synergistic potentiation of the anti-metastatic effect of anti EGFR mAbs by its combination with immunotherapies targeting the ganglioside NGcGM3
23. Abstract B011: Human IL-2 mutant exhibits a higher antitumor efficacy and lower toxicity than wildtype IL-2 in different preclinical contexts
24. Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.
25. Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
26. Computational proteomics pitfalls and challenges: HavanaBioinfo 2012 Workshop report
27. Molecular dissection of the interactions of an antitumor interleukin-2-derived mutein on a phage display-based platform
28. Preclinical Efficacy of Nimotuzumab, an Anti-Egfr Monoclonal Antibody as a Single Agent Therapy in Human GBM u87mg Xenografts
29. Therapeutic Approaches to Target Cancer Stem Cells
30. How Regulatory CD25+CD4+ T Cells Impinge on Tumor Immunobiology: The Differential Response of Tumors to Therapies
31. How regulatory CD25+CD4+T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors
32. When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+T cells
33. Mathematical Models of the impact of IL2 modulation therapies on T cell dynamics.
34. When three is not a crowd: a Crossregulation Model of the dynamics and repertoire selection of regulatory CD4+ T cells.
35. How regulatory CD25(+)CD4(+) T cells impinge on tumor immunobiology? On the existence of two alternative dynamical classes of tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.